Anavex files proxy for Sep 24 meeting, adds two independent directors amid PVG proxy fight

ANAVEX LIFE SCIENCES CORP.

2026 annual meeting set for Sep 24, 2026; record date Jul 31, 2026; PVG owns 0.35% of shares.
Board nominates Gautam Patel and Dr. Adrian Senderowicz as new independent directors; half of board refreshed.
Interim CEO Dr. Terrie Kellmeyer leading; blarcamesine advanced in Alzheimer's, Rett, Fragile X with FDA talks.
Anavex urges votes for six WHITE card nominees; cites PVG slate lacks FDA/drug development expertise.
Nasdaq delinquency notice for late Q1 10-Q received May 20, 2026; listing unaffected, compliance plan filed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.